Acute Coronary Syndrome

Global Acute Coronary Syndrome Market to Reach US$17.6 Billion by 2030

The global market for Acute Coronary Syndrome estimated at US$9.7 Billion in the year 2024, is expected to reach US$17.6 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2024-2030.

The U.S. Market is Estimated at US$2.6 Billion While China is Forecast to Grow at 16.2% CAGR

The Acute Coronary Syndrome market in the U.S. is estimated at US$2.6 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 16.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.3% and 10.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.2% CAGR.

Acute Coronary Syndrome - Key Trends and Drivers

Acute Coronary Syndrome (ACS) is a critical condition that encompasses a spectrum of heart-related issues arising from the sudden reduction of blood flow to the heart muscle. This spectrum includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). The primary underlying cause of ACS is the rupture or erosion of atherosclerotic plaques within the coronary arteries, leading to thrombus (blood clot) formation that partially or fully obstructs the artery. This obstruction compromises oxygen delivery to the heart muscle, causing ischemia and, if untreated, can lead to myocardial infarction (heart attack). Patients typically present with symptoms such as chest pain or discomfort, which may radiate to the arm, neck, jaw, or back, as well as shortness of breath, sweating, nausea, and dizziness. Early and accurate diagnosis is crucial and is typically achieved through a combination of clinical evaluation, electrocardiograms (ECGs), blood tests for cardiac biomarkers like troponins, and imaging studies such as echocardiography or coronary angiography.

Treatment strategies for ACS are aimed at quickly restoring blood flow, minimizing heart muscle damage, and preventing further complications. Pharmacological interventions include antiplatelet agents (e.g., aspirin and P2Y12 inhibitors), anticoagulants (e.g., heparin), beta-blockers, nitrates, and statins, which collectively help in stabilizing the plaque, reducing clot formation, managing symptoms, and preventing further cardiovascular events. For patients with severe artery blockage or ongoing chest pain, interventional procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are employed. PCI, which often involves the placement of drug-eluting stents, has become a cornerstone in ACS management due to its efficacy in reducing restenosis (re-narrowing of the artery). Advances in these interventional techniques, along with the development of new antiplatelet and anticoagulant medications, have significantly improved survival rates and outcomes for ACS patients. Post-acute management includes lifestyle modifications, cardiac rehabilitation, and long-term medication adherence to mitigate the risk of recurrent events.

The growth in the ACS market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases is a major driver, largely due to aging populations and lifestyle-related risk factors such as obesity, physical inactivity, poor diet, smoking, and the rising incidence of diabetes and hypertension. Secondly, advancements in diagnostic technologies are enabling earlier and more precise detection of ACS. High-sensitivity cardiac biomarkers and advanced imaging techniques like cardiac MRI and CT angiography allow for timely and accurate diagnosis, which is critical for effective intervention. Thirdly, the continuous development of novel therapeutic agents and sophisticated interventional procedures is expanding the arsenal of treatment options, thereby improving patient outcomes and driving market growth. Additionally, there is a growing awareness and education about cardiovascular health, which is encouraging more individuals to seek medical attention at the early onset of symptoms, thus increasing the demand for ACS-related healthcare services. Government initiatives and funding focused on enhancing cardiovascular care infrastructure and research are also bolstering the market. Lastly, the integration of telemedicine and digital health solutions is enhancing patient monitoring and follow-up care, enabling better management of ACS and contributing to overall market expansion. These digital advancements allow for remote patient monitoring, timely medical interventions, and improved adherence to treatment regimens, further driving the growth of the ACS market.

SCOPE OF STUDY:

The report analyzes the Acute Coronary Syndrome market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Segment (Acute Coronary Syndrome)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 62 Featured) -

• Amgen, Inc.
• Astellas Pharma, Inc.
• AstraZeneca PLC
• Biological E. Ltd.
• Daiichi Sankyo Co., Ltd.
• Dr. Reddy's Laboratories Ltd.
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Johnson & Johnson
• Momenta Pharmaceuticals, Inc.
• Pfizer, Inc.
• Recordati SpA
• The Medicines Company

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.